Celgene Launches Multiple Myeloma Treatment Pomalyst; Keio Professor Acknowledges Its Efficacy in PFS, OS Improvement

May 26, 2015
Prof. Shinichiro Okamoto Celgene K.K. rolled out on May 21 its multiple myeloma (MM) treatment Pomalyst Capsules (pomalidomide). Pomalyst is indicated for relapsed or refractory MM and is administered to patients who have a treatment history with both the company’s...read more